ADAR1 Capital Management reports acquisition of $12,718.7996 in InMed Pharmaceuticals common shares

ADAR1 Capital Management reported purchases of 9,569 InMed Pharmaceuticals common shares, increasing indirect beneficial ownership to 955,493 shares. Purchases comprised 8,585 shares at $1.33 each and 984 shares at $1.3219 each. Daniel Schneeberger, manager of ADAR1 Capital Management, was also listed as a reporting owner; both are designated 10% owners. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001940272-26-000025), on October 15, 2026, and is solely responsible for the information contained therein. (C)